Evidence map›Paper›PMID 34269966›Full record

ReviewDermatology and therapy2021

Review of the Latest Methods of Epidermolysis Bullosa and Other Chronic Wounds Treatment Including BIOOPA Dressing.

Magdalena Nita, Jacek Pliszczyński, Maciej Kosieradzki, Piotr Fiedor

Open access · goldAbstract readReview
In one paragraph

Review in Dermatology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Magdalena NitaGeneral and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka Street 59, 02-014, Warsaw, Poland.
Jacek PliszczyńskiGeneral and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka Street 59, 02-014, Warsaw, Poland.
Maciej KosieradzkiGeneral and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka Street 59, 02-014, Warsaw, Poland.
Piotr FiedorGeneral and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka Street 59, 02-014, Warsaw, Poland. piotrfiedor@wp.pl.
Medical University of Warsaw · PL

Funding

Narodowe Centrum Badań i Rozwoju STRATERMED2 / 269807/14 / NCBR / 2015
6 · The paper itself

Abstract

Epidermolysis bullosa (EB) is a hereditary genetic skin disorder, classified as a type of genodermatosis, which causes severe, chronic skin blisters associated with painful and potentially life-threatening complications. Currently, there is no effective therapy or cure for EB. However, over the past decade, there have been several important advances in treatment methods, which are now approaching clinical application, including gene therapy, protein replacement therapy, cell therapy (allogeneic fibroblasts, mesenchymal stromal cells), bone marrow stem cell transplant, culture/vaccination of revertant mosaic keratinocytes, gene editing/engineering, and the clinical application of inducible pluripotent stem cells. Tissue engineering scientists are developing materials that mimic the structure and natural healing process to promote skin reconstruction in the event of an incurable injury. Although a cure for EB remains elusive, recent data from animal models and preliminary human clinical trials have raised the expectations of patients, clinicians, and researchers, where modifying the disease and improving patients' quality of life are now considered attainable goals. In addition, the lessons learned from the treatment of EB may improve the treatment of other genetic diseases.

Indexed as

Advanced therapy medicinal productAllogenic human skin equivalentBiological dressingEpidermolysis bullosaHuman skin allograftRare disease

Identifiers

PMID34269966
PMCPMC8484405
OpenAlexW3178044529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.